# QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC.

Source: https://onco.cc/trials/nct07509515/  
OnCo record `nct07509515` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of iparomlimab and tuvonralimab in triple-negative breast cancer, run by Fudan University, not yet recruiting.

## Summary

QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC. is a phase 2, randomised interventional study registered as NCT07509515 by Fudan University, with a registry enrolment figure of 60 participants, started 2026-04-15 and due to reach its primary completion in 2027-09-30. Interventions recorded: QLC5513; QLC5513+QL1706. Conditions listed: Triple-negative Breast Cancer (TNBC). Triple-negative eligibility wording from the registry: "TNBC invasive breast cancer confirmed by histology (specific definition: ER \<1% positive tumor cells by immunohistochemistry are defined as ER negative, PR \<1% positive tumor cells are defined as PR negative, HER2 0-1+ or HER2 ++ but negative by FISH without amplification was defined as HER2 negat". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07509515
- Phase: 2
- Setting: An Open-label, Phase 2 Study of QLC5513 Alone or in Combination With Epalolimab Tovolimab (QL1706) in Previously Treated Advanced or Metastatic TNBC.
- Sponsor: Fudan University
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07509515: https://clinicaltrials.gov/study/NCT07509515

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- drugs: [Iparomlimab and tuvonralimab](https://onco.cc/drugs/iparomlimab-tuvonralimab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07509515.json